David Hale

Mr. Hale is a Founder and Managing Director of Dermata Therpeutics, LLC. He is Chairman and CEO of Hale BioPharma Ventures, LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. He was involved in the formation and development of SkinMedica and served as Executive Chairman and Chairman from 2001 through the Company’s significant revenue growth and the sale of the Company to Allergan in 2012.

Mr. Hale served as Chairman of Santarus, Inc. prior to its sale to Salix Pharmaceuticals in 2014, Micromet prior to its sale to Amgen in 2012 and Somaxon Pharmaceuticals prior to its sale to Pernix in 2013.

Mr. Hale is a serial entrepreneur who has been involved in the formation and/or development of a number of life sciences companies. In addition to the companies above, these include Hybritech, Viagene, Gensia Sicor, CancerVax, Neurelis, MDRejuvena, Clarify Medical, Adigica Health, Oncternal and Neurana. He serves on the board of three public companies, Conatus, BIOCEPT and Cassiopea.